Compare PECO & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | TVTX |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | 320 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 2010 | 2013 |
| Metric | PECO | TVTX |
|---|---|---|
| Price | $38.84 | $50.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $43.00 | ★ $75.21 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 10-26-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | 74.51 | ★ 92.89 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $726,594,000.00 | N/A |
| Revenue This Year | $4.26 | $47.49 |
| Revenue Next Year | $6.62 | $48.73 |
| P/E Ratio | $36.84 | ★ N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $33.10 | $22.59 |
| 52 Week High | $44.38 | $68.73 |
| Indicator | PECO | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 35.14 |
| Support Level | $38.78 | $49.46 |
| Resistance Level | $40.49 | $59.93 |
| Average True Range (ATR) | 0.73 | 2.20 |
| MACD | 0.14 | 0.21 |
| Stochastic Oscillator | 85.16 | 16.43 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.